Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 1;11(5):2742-2748.
eCollection 2018.

Serum miR-342-3p is a novel diagnostic and prognostic biomarker for non-small cell lung cancer

Yingzhi Qin  1   2 , Xiaoyun Zhou  1   2 , Cheng Huang  1   2 , Li Li  1   2 , Hongsheng Liu  1   2 , Naixin Liang  1   2 , Yeye Chen  1   2 , Dongjie Ma  1   2 , Zhijun Han  1   2 , Xiaohui Xu  1   2 , Jia He  1   2 , Shanqing Li  1   2
Affiliations

Serum miR-342-3p is a novel diagnostic and prognostic biomarker for non-small cell lung cancer

Yingzhi Qin et al. Int J Clin Exp Pathol. .

Abstract

Lung cancer is the leading cause of cancer-related mortality and non-small cell lung carcinoma (NSCLC) is the most common type. MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression at the post-transcriptional level. Aberrant expression of miRNAs has been demonstrated to be a prominent feature in NSCLC. The aim of this study was to determine the potential clinical value of serum miR-342-3p in NSCLC. We first evaluated the miR-342-3p levels in NSCLC cell lines, culture media of NSCLC cell lines, and serum samples from NSCLC patients as well as in their respective controls. The associations between serum miR-342-3p levels and clinicopathological parameters as well as clinical outcome were then determined. miR-342-3p expression was significantly downregulated in NSCLC cell lines, culture media of NSCLC cell lines, and the serum samples from NSCLC patients compared to their controls. Serum miR-342-3p discriminated NSCLC patients from healthy individuals. Low expression of serum miR-342-3p was significantly associated with advanced TNM stage and positive lymph node metastasis. In addition, NSCLC patients in the low serum miR-342-3p expression group had remarkably shorter overall survival than those in the high serum miR-342-3p expression group. Serum miR-342-3p was shown to be an independent prognosis factor. In conclusion, serum miR-342-3p might be a promising biomarker for NSCLC that can be used to improve diagnosis and prognosis.

Keywords: Non-small cell lung carcinoma; biomarker; diagnosis; prognosis; serum miR-342-3p.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Expression level of miR-342-3p in NSCLC cell lines and their culture media.
Figure 2
Figure 2
A. Expression level of serum miR-342-3p in NSCLC patients and healthy controls; B. Predictive value of serum miR-342-3p for discriminating SCC patients from healthy controls; C. AD patients from healthy controls and D. NSCLC patients from healthy controls.
Figure 3
Figure 3
Association between serum miR-342-3p level and overall survival in NSCLC.
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. - PubMed
    1. Patel JN, Ersek JL, Kim ES. Lung cancer biomarkers, targeted therapies and clinical assays. Transl Lung Cancer Res. 2015;4:503–514. - PMC - PubMed
    1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–594. - PMC - PubMed
    1. Henschke CI, Yankelevitz DF. CT screening for lung cancer: update 2007. Oncologist. 2008;13:65–78. - PubMed
    1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297. - PubMed

LinkOut - more resources